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Abstract
Increased intraocular pressure is arguably the most important, and cur-
\OX^Vc^ROYXVcWYNS	KLVO\S]UPKM^Y\PY\QVK_MYWK^Y_]YZ^SMXO_\YZK^Rc
Ocular hypertension is often encountered by clinicians in daily practice and 
is expected to be seen with increasing frequency as the population ages. 
Awareness and understanding of the extensive research performed on 
this subject, with particular focus on the work of the Ocular Hypertension 
Study Group, are critical for comprehensively assessing the risk of conver-
sion to glaucoma. Although management decisions can be complex, they 
can be aptly handled by the well-informed optometrist in consultation with 
their patients. 
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The primary goals of the optometrist are to prevent disease and to maintain and maximize visual health and function. Glaucomatous optic neuropathy is the leading cause of irreversible blindness world-wide; the current global prevalence of glaucoma in persons between 40 and 80 years of age is 3.54%, 
or approximately 64.3 million individuals.1 As the population continues to simultaneously increase and age, 
this number is expected to increase to 76.0 million by 2020 and to a staggering 111.8 million by 2040.1 Specifi-
cally in Canada, it was estimated that 409,000 people had glaucoma in 2002-2003.2 The National Coalition 
for Vision Health has predicted a 105% increase in the number of Canadians who will be rendered blind as 
a result of glaucoma, from 9,500 cases in 2006 to 19,400 cases by 2031.2 This disease imposes a substantial 
burden on both the individual and society as a whole, but it can be combated by the application of optometry. 
Although our understanding of glaucomatous optic neuropathy continues to expand, increased intraocular 
Z\O]]_\O39:\OWKSX]^ROWY]^SWZY\^KX^WYNSPSKLVO\S]UPKM^Y\PY\^RS]YZ^SMXO_\YZK^Rc
3 As a result, sub-
]^KX^SKVOXO\QcRK]LOOXNO`Y^ON^Y\O]OK\MRYXYM_VK\RcZO\^OX]SYX922S]^Y\SMKVVc92aK]MYX]SNO\ON
to be synonymous with glaucoma, or a patient was automatically considered to be in a “glaucoma suspect” 
category.4,5 At present, OH is defined as an IOP greater than 2 standard deviations from the mean of a normal 
adult population, with “normal” visual fields and a “normal” optic disc structure.6 According to Armaly, “nor-
WKVv39:LK]ONYX1YVNWKXXKZZVKXK^SYX^YXYWO^\c1+>S]ObZOM^ON^YLO ± 2.5 mmHg.7 According to 
this distribution, approximately 95% of the population would be expected to have an IOP under 21 mmHg and 
98% would have an IOP under 24 mmHg. However, these are statistical averages based on the presumption 
of a symmetrical Gaussian distribution. In actuality, studies have shown that IOP in a population is not dis-
tributed symmetrically, but rather is skewed toward higher pressure.8-11 The fact that the distribution curve is 
skewed cannot be regarded as evidence that eyes with IOP above a statistical normal have a pathological pro-
cess.12 Accordingly, there is some uncertainty regarding the influence of statistically high IOP in individual 
patients. It is critical that the optometric community have a strong understanding of the prevailing evidence 
on OH to reduce this uncertainty.
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EPIDEMIOLOGY OF OH 
Fortunately, most patients with OH do not develop glaucoma. An analysis of multiple studies shows that the 5-year in-
MSNOXMOYPZ\SWK\cYZOXKXQVOQVK_MYWK:9+1SX_X^\OK^ONYM_VK\RcZO\^OX]S`OMK]O]\KXQO]P\YW#^Y
13 In 
contrast, the 5-year incidence of POAG in treated ocular hypertensive patients ranges from 4.4 to 15%, which repre-
sents a substantial reduction over that in untreated patients. Although this analysis suggests that the overall incidence 
of glaucoma development is low, the visual and functional consequences in patients who actually develop glaucoma can 
be devastating. When deciding upon whether or not to treat, it is helpful to understand the prevalence of OH in various 
populations, and thus the potential impact of therapeutic intervention. General estimates of the overall prevalence of 
ocular hypertension have been reported to range from 4 to 7% of the US population over age 40, and this prevalence in-
creases with age.14 Thus, an estimated 4.8 to 9.5 million people in the US have elevated IOP without detectable glaucoma-
tous damage using current clinical tests.15>RO`K\SK^SYXSXZ\O`KVOXMOMKXLOO`OXQ\OK^O\aROX]ZOMS	MZYZ_VK^SYX]K\O
examined. For example, the prevalence of ocular hypertension ranged from 2.3% in patients 43–49 years of age to 7.7% in 
those 75–79 years of age in the widely cited Beaver Dam Study, which included a primarily Caucasian population in Wis-
consin, USA.16 In a study with similar demographics, the Blue Mountain Eye Study, which included an older Australian 
community of largely white subjects of northern European descent, the age–standardized prevalence of OH was 5.15% in 
patients aged 50 and older in the year 2000.17 The authors projected that the prevalence in this population would reach 
5.48% in the year 2030.18 In the Los Angeles Latino Eye Study, in Latinos from California, the 4-year incidence of OH, de-
	XONK]39:(WW2QKXN^ ROKL]OXMOYPYZ^SMNS]MNKWKQOY\KLXY\WKV` S]_KV	OVN\O]_V^]aK] KP^O\KNT_]^SXQPY\
the age distribution.19 The Chennai Eye Disease Incidence Study, in a population of Southern Indians aged 40 and older, 
PY_XN^RK^^RO cOK\SXMSNOXMOYPYM_VK\RcZO\^OX]SYXNO	XONK]39:KLY`O^RO#!
th percentile of the population with 
no evidence of glaucoma, was 2.17%.20>R_]^ROOZSNOWSYVYQcYP92`K\SO]aSNOVcKWYXQNSPPO\OX^]ZOMS	MZYZ_VK^SYX]
and the impact of treatment may be greater in some communities than others.
OH HISTORICAL PERSPECTIVE 
The general opinion in 1862, dating back to Donders, was that ocular hypertension nearly always progressed with in-
creasingly higher IOPs, and was synonymous with glaucoma.4 This viewpoint persisted into the late 1950s. By the 1960s, 
S^RKNLOMYWOSXM\OK]SXQVcYL`SY_]^RK^^ROYL]O\`ONZ\O`KVOXMOYPQVK_MYWKNO	XONLc^RO]^\SM^O\M\S^O\SKYP\KS]ON
Z\O]]_\OM_ZZONNS]MKXN	OVNVY]]aK]^YYVYa^Y]_ZZY\^^RORcZY^RO]S]^RK^Z\O]]_\O]LOcYXN^RORSQRO\OXNYP^RO
Gaussian distribution inevitably led to glaucoma.21 Although this observation was innovative, it was still not clear whether 
IOP in patients with OH would continue to rise over time or how often ocular hypertension was a precursor of mani-
fest glaucoma. A 1964 study by Linner and Stromberg on untreated ocular hypertensives determined that IOP in these 
patients did not tend to rise over time or show signs of glaucoma.4 In 1968, Graham reported a follow-up study of 232 
YM_VK\RcZO\^OX]S`O]Y`O\WYX^R]KXNYXVcZK^SOX^NO`OVYZONK	OVNNOPOM^
22 In 1969, in a 10-year study on subjects 
K^KVVVO`OV]YP^OX]SYX+\WKVcPY_XN^RK^ZK^SOX^]aS^RSXS^SKVKZZVKXK^SYX\OKNSXQ](WW2QRKNK`O\cVYaSXMSNOXMO
YP`S]_KV	OVNVY]]KV^RY_QR^RO\OaK]XY^]_\Z\S]SXQVcK^OXNOXMcPY\	OVNNOPOM^]^YLOWY\OZ\O`KVOX^K^RSQRO\Z\O]-
sures.23 Multiple small retrospective studies on OH were performed over the next few decades.24-32 The results of these 
studies were inconclusive; some demonstrated that treatment was effective and others demonstrated that treatment was 
XY^OPPOM^S`OPY\]VYaSXQ^ROMYX`O\]SYX^YQVK_MYWK:\YLVOWK^SMKVVc^RO]O]^_NSO]RKNXYMYX]S]^OX^NO	XS^SYXYPQVK_-
MYWKaO\OVSWS^ONLcZYY\VcOP	MKMSY_]WONSMK^SYX]KXN_]ON` K\cSXQOXNZYSX^]+]K\O]_V^YP^ ROMYX
SM^SXQWO^RYN]
NO	XS^SYX]KXN	XNSXQ]^RO]O]^_NSO]Z\O`OX^ON^ROK^^KSXWOX^YPKMYX]OX]_]^RK^aY_VNLO_]OP_V^YMVSXSMSKX]SX^ROS\
^\OK^WOX^NOMS]SYX]0_\^RO\WY\OS^aK]_XMVOK\aRO^RO\^ ROLOXO	^]YP^ \OK^WOX^Y_^aOSQRON^ RO\S]U]K]]YMSK^ONaS^R
treatment.333XKXOPPY\^^Y	XKVVcKMRSO`OKMYX]OX]_]YX^ROWKXKQOWOX^YP^RO]OZK^SOX^]^ROVKXNWK\U9M_VK\2cZO\-
^OX]SYX>\OK^WOX^=^_Nc92>=aK]SXS^SK^ONSX##
OCUL AR HYPERTENSION TREATMENT STUDY
=ZOMS	MKVVc92>=]Y_QR^^YO`KV_K^O^RO]KPO^cKXNOP	MKMcYP^YZSMKVYM_VK\RcZY^OX]S`OWONSMK^SYXSXZ\O`OX^SXQY\
NOVKcSXQ^ROYX]O^YP`S]_KV	OVNVY]]KXNY\YZ^SMXO\`ONKWKQOSX]_LTOM^]aS^RYM_VK\RcZO\^OX]SYXaRYaO\OK^WYN-
erate risk for developing primary open angle glaucoma.34 OHTS was a multicenter; convenience randomized controlled 
^\SKV<->SX`YV`SXQ  YM_VK\RcZO\^OX]S`OZK^SOX^]aRYaO\OK^WYNO\K^O\S]UPY\NO`OVYZSXQQVK_MYWK.OWY-
graphically, 69% of the participants were Caucasian, 25% were African-American and 3.6% were of Hispanic origin. Strict 
eligibility criteria were required for participation. Patients were randomized to a treatment group or a close observation 
group. The goal in the treatment group was to achieve an IOP reduction of 20% or more from baseline and to reach an 
IOP level under 24 mmHg. The study was split into two phases. Phase I had a mean duration of 72 months. At 60 months, 
^ROM_W_VK^S`OZ\YLKLSVS^cYPNO`OVYZSXQMVSXSMKVVcNO^OM^KLVOQVK_MYWKNO	XONK]\OZ\YN_MSLVO`S]_KV	OVNKLXY\WKVS-
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^SO]Y\\OZ\YN_MSLVOMVSXSMKVVc]SQXS	MKX^YZ^SMNS]MNO^O\SY\K^SYXK^^\SL_^KLVO^YQVK_MYWKaK]SX^ROWONSMK^SYX
group and 9.5% in the observation group.33 Based on the greater than 50% relative risk reduction and the absolute risk re-
duction of 5.1% in the treatment group, the authors concluded that the use of medications was clearly effective in delaying 
or preventing the onset of POAG in individuals with OH. These results, however, failed to answer many critical questions 
that could assist the clinician in decision-making when assessing these patients. 
:RK]O33YP92>=K]ZS\ON^YNO^O\WSXOaRO^RO\KVVZK^SOX^]]RY_VNLO^\OK^ONaROX^ROc]RY_VNLO^\OK^ONKXN]ZOMS	-
cally whether there was a penalty to delaying treatment. All participants from phase I were invited to participate in phase 
II, and 1,366 patients continued in the study. Ocular hypotensive therapy was started in the original observation group, 
and the original treatment group continued their medications. Phase II lasted for a mean of 5.5 years and included 1,159 
active patients at the study’s 13-year end point.15 This created a delayed treatment group to compare to the so-called 
early treatment group. After 13 years, the overall percentage of patients who were initially randomized to the observation 
group that developed POAG was 22%, compared with 16% in the original treatment group, which means that treatment 
was associated with a 27% relative reduction in the incidence of POAG.15 Glaucoma was detected at a median of 6.0 years 
in the observation group and 8.7 years in the treatment group.15 These overall 13-year outcomes further validated phase 
I, and reinforced the value of treatment in delaying or preventing glaucoma. In addressing whether there was a penalty 
to delaying treatment, the authors concluded that there was only a modest overall penalty. This was rooted in the fact 
that the 13-year incidence of POAG decreased substantially in patients from the observation group once medication was 
initiated in phase II. The cumulative proportion of participants who developed POAG in phase II was 11% in the original 
observation group and 12% in the original medication group, which was an incremental difference. They suggested that 
this result indicates that there is no acceleration of damage if treatment is initially withheld, since the frequency of devel-
oping the disease clearly did not increase once treatment was initiated. However, they did note that there was a greater 
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disease burden on the original observation group, with more eyes reaching the end points regarding both glaucomatous 
YZ^SMNS]MKXN`S]_KV	OVN"YL]O\`K^SYX`]^\OK^WOX^^RONO`OVYZWOX^YPLSVK^O\KVQVK_MYWK YL]O\`K^SYX`]
^\OK^WOX^KXNK]SQXS	MKX^VcaY\]OZK^^O\X]^KXNK\NNO`SK^SYX:=.]VYZO
15 
A more detailed analysis established risk subgroups that were divided into tertiles of low, moderate and high risk. These 
subgroups had baseline predicted 5-year risks of developing POAG of )6%, between 6 and 13%, and *13%, respectively.35 
The 13-year results showed that the incidence of POAG in the lowest-risk subgroup was 8% in the observation group 
KXN!SX^RO^\OK^WOX^Q\Y_ZaRSMR\O
OM^]K]SWZVS	ON\OVK^S`O\S]U\ON_M^SYX<<<YPKZZ\YbSWK^OVcKXNKX
KL]YV_^O\S]U\ON_M^SYX+<<YP3X^ROWYNO\K^O\S]U]_LQ\Y_Z#YPZK^SOX^]SX^ROY\SQSXKVYL]O\`K^SYXQ\Y_Z
developed POAG versus 14% in the treatment group; a RRR of 26% and an ARR of 5%. In the highest-risk subgroup, 40% 
of patients in the observation group and 28% in the treatment group developed POAG; a RRR of 30% and an ARR of 12%.15 
>ROK_^RY\]MYXMV_NON^RK^^ROcOK\\O]_V^]]RYaON^RK^RSQR\S]U92ZK^SOX^]WSQR^LOXO	^P\YWWY\OP\O[_OX^
follow-up examinations and earlier treatment, while treating the lowest-risk OH patients provided little value: these 
patients required less-frequent clinical evaluation and would not suffer from delayed treatment. They also suggested 
that if, in fact, there was little harm to delaying treatment, with no increased incidence of the disease once treatment 
was initiated, then watchful waiting could be another viable option in all patients. Unfortunately, they could not provide 
]ZOMS	MQ_SNKXMOYXaRK^MYX]^S^_^ONaK^MRP_VaKS^SXQ]SXMOVYXQ^O\WP_XM^SYXKVMYX]O[_OXMO]aO\O_XUXYaX>ROc
estimated that this question could be answered with an additional 5-20 years of follow-up.15
:RK]O33NO^O\WSXON^RK^ZK^SOX^]SX^ROYL]O\`K^SYXQ\Y_ZRKNK]SQXS	MKX^VcaY\]O:=.]VYZO>RS]\O]_V^RKNVSWS^ON
SX
_OXMORYaO`O\]SXMOMRKXQOaK]NO	XONLK]ONYXRYaPYVVYa_Z`S]_KV	OVN\O]_V^]NSPPO\ONMYWZK\ON^Y^RY]OSX
an age-matched normal, which is known as an event analysis.36@S]_KV	OVN^O]^SXQObRSLS^]LY^RSX^\K^O]^KXNSX^O\^O]^
variability of between 2 and 3dB, which can undermine the correct interpretation of the patient’s visual status37 The 
92>=SX`O]^SQK^Y\]Y\SQSXKVVcNO	XONK`S]_KV	OVNKLXY\WKVS^cK]MYX]OM_^S`OKLXY\WKV	OVN]aS^R^ROKLXY\WKV-
S^cSX^RO]KWOVYMK^SYXKXNYX^RO]KWOSXNObLOVSO`SXQ^RS]^YLO]_P	MSOX^^YNO^OM^WOKXSXQP_VMRKXQO
34 Under this 
SXS^SKVM\S^O\SYXK]^KQQO\SXQ" YP	\]^YMM_\\SXQKLXY\WKV`S]_KV	OVN]aO\OXY^MYX	\WONYX^ROXOb^\O^O]^
38 This 
SVV_]^\K^O]^ROSXRO\OX^NSP	M_V^cSXMYX	\WSXQKWOKXSXQP_V`S]_KV	OVNKLXY\WKVS^caS^RVSWS^ON^O]^SXQ_]SXQK^O]^
with known variability. This result obviated the fact that the initial abnormality criterion was unacceptable, prompting 
^ROSX`O]^SQK^Y\]^ YMRKXQO^ ROM\S^O\SYXPY\KLXY\WKVS^c^ YKWY\O]^\SXQOX^\O[_S\OWOX^YPMYX]OM_^S`OKLXY\WKV	OVN]
with the abnormality in the same location and on the same index.38 +V^RY_QR^RO\O`S]ON92>=`S]_KV	OVNKLXY\WKVS^c
M\S^O\SYXMY_X^O\ON^RO
_M^_K^SYXSX^O]^SXQ^R_]Z\Y`SNSXQWY\O\OZOK^KLVOKXNWOKXSXQP_VNK^K^RO]^_Nct]_]OYPKX
O`OX^KXKVc]S]^YMYX	\WMRKXQORKNS^]NS]KN`KX^KQO]>ROVSWS^K^SYX]YPKXO`OX^KXKVc]S]SXMV_NO^RO_XNO\_^SVSdK^SYX
of many intervening VF tests when determining if change has occurred and the lack of an estimated rate of change.36 A 
LO^^O\SXNSMK^Y\YPMRKXQOUXYaXK]K^\OXNKXKVc]S]^\KMU]SX^\K]_LTOM^VYXQS^_NSXKV`K\SKLSVS^cYP]ZOMS	M`S]_KV	OVN
ZYSX^]Y\^ROOX^S\O	OVNS^]OVP
39 De Moraes et al.39 , in a follow-up OHTS publication, used a trend analysis to compare 
^RO\K^OYP`S]_KV	OVNMRKXQOLOPY\OKXNKP^O\^ROSXS^SK^SYXYP^\OK^WOX^SXZK^SOX^]aRYaO\OY\SQSXKVVcK]]SQXON^Y
YL]O\`K^SYX>\OK^WOX^NOM\OK]ON^ROQVYLKV`S]_KV	OVNWOKXNO`SK^SYX\K^OYPMRKXQOLc!KXN^ROVYMKVSdON\K^OYP
MRKXQOLc>ROLOXO	^YP^\OK^WOX^Ob^OXNONLY^R^YZK^SOX^]aRYMYX`O\^ON^Y:9+1KXN^RY]OaRYNSNXY^>RO
K_^RY\]XY^ON^RK^^RO\K^OYPMRKXQOSXZK^SOX^]aRYMYX`O\^ON^YQVK_MYWKaK]]^SVV]SQXS	MKX^KXN]_QQO]^ON^RK^^RO
^K\QO^39:LOKNT_]^ONWY\OKQQ\O]]S`OVcSX^ RO]OZK^SOX^]^ RKXaROX^ ROcaO\OMVK]]S	ON]SWZVcK]YM_VK\RcZO\^OX]S`O]
Although the OHTS had a tremendous impact on our understanding of these patients, the authors noted some 
limitations to the study:
 1. The target of a 20% reduction in IOP was not considered to be ideal; it was simply realistic for the 
medications that were available at the start of the study. It is conceivable that the percent risk reduction 
would have been even greater in the treatment group if a more aggressive target had been set and achieved. 
2. OHTS was not designed to be an assessment of ocular hypertension in the general population. This was 
a convenience study involving healthy volunteers and is not generalizable to patients who do not have 
baseline characteristics similar to those in the OHTS subjects.
3. The threshold for diagnosing POAG was very high given the available diagnostic techniques at the time. 
4. One-third of OHTS participants were considered to be high-risk based on the strict criterion of IOP of 24-
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32 mmHg in the higher study eye.15 The authors speculated that most of the general public with OH likely 
RK`OVYaO\39:]^RKX^RS]M\S^O\SYXKXNMYX]O[_OX^VcRK`OKVYaO\\S]UZ\Y	VO^RKX^ROZK^SOX^]SX`YV`ON
SX^RO]^_Nc>RO^aYZRK]O]YP^RS]`O\caOVVMYX^\YVVON]^_NcNO	XS^S`OVc]RYaON^RK^OK\Vc^\OK^WOX^
of patients with high-risk ocular hypertension successfully delayed or prevented the development of 
glaucoma, whereas early treatment of low-risk patients was of little value. 
IMAGING IN OH PATIENTS
Trends in the diagnosis and management of glaucoma show a substantially increased reliance on objective imaging of the 
YZ^SMNS]M\O^SXKVXO\`O	LO\VKcO\KXNQKXQVSYXMOVVMYWZVObaS^RKMYXM_\\OX^NOM\OK]ON\OVSKXMOYX`S]_KV	OVN^O]^-
ing.40 When OHTS began, these imaging capabilities were not readily available, and structural glaucoma changes were 
NO^O\WSXONLcMYWZK\SXQ]^O\OY]MYZSMNS]MZRY^YQ\KZR]9XOYP^RO	\]^MYWWO\MSKVVcK`KSVKLVO^OMRXYVYQSO]^RK^MY_VN
YLTOM^S`OVcK]]O]]^ROYZ^SMNS]MKXN\O^SXKVXO\`O	LO\VKcO\aK]^ROMYXPYMKV]MKXXSXQVK]O\YZR^RKVWY]MYZO-=69
]ZOMS	MKVVc^ RO2OSNOVLO\Q<O^SXKV>YWYQ\KW2<>3XKZ\Y]ZOM^S`OKXMSVVK\c]^_Nc^ Y92>=^ ROSX`O]^SQK^Y\]]Y_QR^
^YNO^O\WSXO_]SXQ^ RO2<>aRO^RO\YZ^SMNS]M^ YZYQ\KZRSMWOK]_\OWOX^]K\OKXKMM_\K^OZ\ONSM^Y\YP` S]_KV	OVNVY]]
as well as how effective the CSLO is in detecting the presence and progression of glaucomatous optic disc damage.41 The 
]^_Nc\O`OKVON^RK^W_V^SZVOLK]OVSXOYZ^SMXO\`OROKNZK\KWO^O\]aO\O]SQXS	MKX^VcK]]YMSK^ONaS^R^RONO`OVYZWOX^
YPQVK_MYWK^Y_]NS]MY\`S]_KV	OVNNKWKQO
42
=ZOMS	MKVVc^ROLK]OVSXO1VK_MYWK:\YLKLSVS^c=MY\O1:=7YY\	OVN]
<OQ\O]]SYX+XKVc]S]7<+KXN]^O\OYWO^\SMZK\KWO^O\]]RYaON]SWSVK\Z\ONSM^S`OKLSVS^SO]K]WYNOV]_]SXQ^ROZRY-
tograph-based horizontal cup-to-disc ratio.43 The study also compared the rate of structural change in OH patients who 
developed glaucoma to that in those who did not. The authors found that the rate of rim area loss in patients who devel-
YZONQVK_MYWKaK]	`O^ SWO]PK]^O\^ RKX^ RK^SX^ RY]OaRYNSNXY^NO`OVYZQVK_MYWK
44 Although this study only involved 
-=69^ OMRXYVYQcS^S]\OK]YXKLVO^ YMYXMV_NO^ RK^Y^RO\PY\W]YPYLTOM^S`OSWKQSXQ^ OMRXYVYQcWKcZVKcK]SQXS	MKX^\YVO
in both helping to predict who is at risk for developing glaucoma and how a practitioner can view the rate of change when 
ascertaining that the patient is converting to POAG. 
9Z^SMKVMYRO\OXMO^ YWYQ\KZRc9->aRSMRaK]XY^MYWWO\MSKVVcK`KSVKLVOK^^ RO^ SWOYP92>=\OM\_S^WOX^S]XYa
_LS[_S^Y_]SXQVK_MYWKWKXKQOWOX^KXNMKXLO_]ON^ YNO^OM^NS]OK]OcOK\]Z\SY\^ Y\OZOK^KLVO` S]_KV	OVNVY]]5_KXQ
et al.45SX`O]^SQK^ON^ROO]^SWK^ONVOKN^SWOQKSXONLc\O^SXKVXO\`O	LO\VKcO\<806WOK]_\OWOX^]_]SXQ9->PY\
detecting glaucoma prior to the development of VF loss in glaucoma suspects. They estimated that up to 35% of eyes 
RK`OKXKLXY\WKVK`O\KQO<806^RSMUXO]]cOK\]LOPY\O^RONO`OVYZWOX^YP`S]_KV	OVNVY]]KXN#YPOcO]RK`OKX
KLXY\WKV<806^RSMUXO]]"cOK\]LOPY\O`S]_KV	OVNVY]]3XM\ONSLVc^RO]O\O]_V^]K\OMYX]S]^OX^aS^R^RO	XNSXQLc
Sommer et al.46SX##^RK^ YP]^_NSONQVK_MYWKOcO]RKNZRY^YQ\KZRSMKVVcNO^OM^KLVOXO\`O	LO\NOPOM^] cOK\]
LOPY\O^RONO`OVYZWOX^YPQVK_MYWK^Y_]	OVNNOPOM^]+V^RY_QR^RO92>=KXMSVVK\c]^_NcaK]ZO\PY\WONaS^R-=69
technology, RNFL assessment with OCT has now been shown to be superior to CSLO for detecting pre-perimetric 
glaucomatous damage in glaucoma suspects.47 Colombo et al.48, in a study of 68 untreated ocular hypertensives, as-
sessed the correlation between the 5-year risk of developing glaucoma and the condition of the optic nerve head and 
\O^SXKVXO\`O	LO\O`KV_K^ONLc9->]MKXXSXQVK]O\ZYVK\SWO^\cKXN-=69>ROcPY_XN]SQXS	MKX^MY\\OVK^SYX]LO-
tween OCT RNFL parameters and an individual’s risk to develop POAG that did not exist with the other two technolo-
gies. Multiple smaller studies have determined that either mean RNFL or segmental RNFL measurements are thinner 
in OH patients than in normals. However, these studies did not demonstrate any uniform OCT parameters that might 
reliably predict the development of early glaucoma in OH patients.49-55 Since OCT is superior to CSLO, it would be 
interesting to see the predictive capability of OHTS ancillary imaging if OCT had been available and used in that study. 
Additionally, although the sensitivity and repeatability of OCT technology is indisputable, the fact that Sommer et al. 
achieved results similar to those of Kuang et al. 24 years earlier reinforces the notion that photographic assessment of 
^RO\O^SXKVXO\`O	LO\VKcO\S]KZYaO\P_V^YYV^RK^]RY_VNXY^XOMO]]K\SVcLO\OXNO\ONYL]YVO^O
RISK FACTORS
In the management of any chronic or potentially chronic disease state, the primary care optometrist’s principal job 
is to appropriately manage risk to prevent adverse outcomes. A small subset of OH patients will develop glaucoma, 
ultimately with the risk of visual impairment. A review of the available literature shows that the 15-year risk estimates 
of unilateral blindness range from 3.1 to 10.5% in untreated OH patients and 0.9 to 8.6% in treated OH patients.56,57 
Although these percentages seem low, their impact is severe. An understanding of the importance of various risk fac-
tors for progression and their application is pivotal to providing an informed consultation with the patient to reduce 
^ROS\\S]UYPLVSXNXO]]3X^ROZVKXXSXQZRK]OYP92>=LK]OVSXONOWYQ\KZRSMKXNMVSXSMKVPKM^Y\]aO\OSNOX^S	ON
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that might predict which patients would be more likely to develop glaucoma. Six years into the study, the relevant risk 
factors for conversion to glaucoma from OH were baseline age, vertical and horizontal cup-disc ratio, PSD, central cor-
XOKV^RSMUXO]]-->KXNSX^\KYM_VK\Z\O]]_\O
58 Interestingly, although multiple studies have shown an association 
between diabetes and the development and progression of glaucoma, OHTS initially found that diabetes conferred a 
protective effect against the development of POAG.58-63 The authors later acknowledged methodological issues that 
WSQR^KMMY_X^PY\^RS]Z\Y^OM^S`OOPPOM^AS^R^RO_]OYPWY\O]ZOMS	MNO	XS^SYX]PY\KZ\O]OX^MYXNS^SYXYPNSKLO^O]
KRS]^Y\cYPNSKLO^O]aK]XY^]SQXS	MKX^VcK]]YMSK^ONaS^RZ\Y^OM^SYXKQKSX]^QVK_MYWK
64 Additionally, although it has 
been suggested that the prevalence of POAG in African-Americans is 4-5 times higher than that in individuals of Eu-
ropean descent, after adjusting for a thinner central corneal thickness and a larger cup-to-disc ratio at baseline in this 
NOWYQ\KZRSM\KMOS^]OVPaK]XY^K]^K^S]^SMKVVc]SQXS	MKX^Z\ONSM^Y\YP^RONO`OVYZWOX^YPQVK_MYWK
58,65-68 
The strongest and arguably most novel of the independent predictive risk factors noted above was CCT. Simply put, 
the risk of developing POAG is inversely correlated with the CCT. The study showed that average CCT was 553.1±38.8 
μm among study participants who developed POAG and 574.3±37.8 μm among those who did not develop glaucoma. 
Subjects were further divided into three thickness subgroups: thin, intermediate and thick. The thin subgroup (aver-
age CCT of 530.8μWRKNKQ\OK^O\^RKX^R\OOPYVNRSQRO\\S]UYPNO`OVYZSXQQVK_MYWK^RKX^RO^RSMU]_LQ\Y_ZK`O\-
age CCT of 613.5μW58>RO]O	XNSXQ]WKXNK^O^RO_]OYP-->^YO`KV_K^O\S]USXZK^SOX^]aS^RYM_VK\RcZO\^OX]SYX
More recent studies on glaucoma have suggested that the relationship between the cornea and glaucoma involves 
more than just the anatomic thickness of that anterior tissue.693^MKXLONSP	M_V^^YNSPPO\OX^SK^OQVK_MYWK^Y_]OcO]
from OH eyes on the basis of CCT alone, since there is a substantial overlap in thickness between the two groups.70 
+V^RY_QRMY\XOKVRc]^O\O]S]-2aK]XY^SXMV_NONSX^ROZ\ONSM^S`O\S]UPKM^Y\]K]]O]]ONLc92>=]SXMOS^aK]XY^
on the radar at the time, it has since emerged as an important risk factor for the development of, severity of, and rate 
YP`S]_KV	OVNVY]]SXQVK_MYWK
71-77 Corneal hysteresis is considered to be a measure of corneal viscous dampening, 
and thus directly assesses the cornea’s resistance to deformation.78 It has been proposed that the characteristics of the 
MY\XOKV^S]]_OS^]OVP]_MRK]^ROKLSVS^c^Y\O]S]^NOPY\WK^SYXWSQR^\O
OM^^ROMYX]^S^_^SYXYP^ROOb^\KMOVV_VK\WK^\Sb
/-7=SXMO^ROMY\XOK]MVO\KZO\SZKZSVVK\c\SXQKXNVKWSXKM\SL\Y]KK\OO]]OX^SKVVcMYX]^\_M^ONYP^RK^]KWO/-7
it is plausible that their biomechanical characteristics might be similar.74 It has been proposed that an eye with more 
NOPY\WKLVOKX^O\SY\YM_VK\^S]]_O]MY\XOKWSQR^KV]YLOK^RSQRO\\S]UPY\QVK_MYWK^Y_]NKWKQO]OMYXNK\c^Y^ROOP-
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fect of IOP on posterior ocular tissues.79 It has additionally been demonstrated that eyes with lower CH seem to be as-
sociated with altered optic nerve head compliance during the adjustment of IOP.79 Multiple studies have demonstrated 
^RK^ZK^SOX^]aS^R`K\SY_]PY\W]YPQVK_MYWKRK`O]SQXS	MKX^VcVYaO\MY\XOKVRc]^O\O]S]`KV_O]^RKXXY\WKV]
71,72,80-86 
Sullivan-Mee and co-workers70 assessed CH, CCT and IOP in patients with OH and POAG and found that only CH was 
SXNOZOXNOX^VcK]]YMSK^ONaS^R:9+1KXN-2aK]^ROYXVc`K\SKLVO^RK^NSPPO\OX^SK^ON92P\YW:9+1aS^R]SQXS	-
cantly lower CH in the POAG group. Consequently, the measurement of corneal hysteresis in OH patients can provide 
additional information that can help the optometrist when assessing the risk of conversion.
>ROZ\O]OXMOYPYZ^SMNS]MROWY\\RKQO.2S]aSNOVcKMMOZ^ONK]YXOYP^RO]^\YXQO]^\S]UPKM^Y\]PY\^RONO`OVYZ-
ment and progression of glaucoma.87,88 DH is rarely found in normal eyes and its prevalence in OH patients has been 
reported to range from 0.04% to 10%.89 Although patients with DH at baseline were excluded from participation 
in OHTS, the investigators did monitor their presence over an average follow-up of 96.3 months. They sought to 
compare the rate of DH detection by clinical examination and photographic review, to assess the incidence of and 
predictive factors for DH in annual disc photos, and to determine whether DH predicted the development of POAG 
in the OHTS participants.90 They found that only 16% of DH were detected by clinical examination, and 84% were 
detected by photographic review. The discrepancy between clinical and photographic detection in this study has 
not been noted in other studies.91,92 The baseline risk factors in participants with DH were similar to those in partici-
pants who developed glaucoma: older age, increased cup-to-disc ratio, and thinner CCT. Patients with DH were six 
times more likely to develop glaucoma than those without DH. The cumulative incidence of POAG in eyes with DH 
was 13.6%, compared to 5.2% in eyes without DH, suggesting that DH are additional predictive risk factors for the 
development of POAG. However, the authors cautioned that, since 86.7% of the participants with DH did not reach 
a glaucomatous end point by the end of follow-up, it could not be concluded that disc hemorrhages are synonymous 
with glaucoma. Furthermore, they suggested that the initial results do not direct practitioners to treat all patients 
with OH who have DH.90 In a *cOK\PYVVYa_Z]^_Nc^RO92>=Q\Y_ZMYWZK\ON^RO\K^OYP`S]_KV	OVNMRKXQO
SXOcO]aS^RKXNaS^RY_^.2$^RO\K^OYP`S]_KV	OVNNO^O\SY\K^SYXSXOcO]aS^R.2aK]WY\O^RKX^aSMO^RK^SX
eyes without DH. Randomization to the treatment group decreased the likelihood of developing DH, implying that 
treatment may provide a protective effect against DH. The authors concluded that the presence of DH should alert 
the managing clinician to a heightened risk that may require more aggressive intervention to prevent a negative 
clinical outcome.93 Given the negative prognostic importance of DH, to accurately assess the risk and appropriately 
intervene, it is critical that the clinician look for the sometimes subtle presence of DH using a combined approach 
of concentrated clinical examination and stereoscopic disc photography.87,88
RISK ASSESSMENT/ RISK CALCUL ATORS
=SXMO92>=NOWYX]^\K^ON^RK^^\OK^WOX^aK]OP	MKMSY_]S^WSQR^]OOW\OK]YXKLVO^YMYXMV_NO^RK^^\OK^SXQKVVZK^SOX^]
with OH is an appropriate preventative measure that hedges against glaucoma. However, after an exhaustive analysis, the 
OHTS investigators concluded that the treatment of all ocular hypertensive individuals is neither medically indicated nor 
OMYXYWSMKVVcT_]^S	KLVON_O^ Y^ RORSQRZ\O`KVOXMOYP^ ROMYXNS^SYX^ ROVYaMYX`O\]SYX\K^O^ Y:9+1KXN^ ROMY]^SXMYX-
venience, and possible adverse effects of treatment.14>ROSWZY\^KX^ZYSX^S]^RK^^RO92>=SNOX^S	ON^RK^K]_L]^KX^SKV
]_]MOZ^SLVOWSXY\S^cYPZK^SOX^]MKXLOXO	^P\YWWONSMKVSX^O\`OX^SYXKXNSNOX^S	MK^SYXYP^RO]OSXNS`SN_KV]S]M\S^SMKV
=ZOMS	MKVVc^ROcOK\\S]UYPMYX`O\^SXQ^YQVK_MYWKaK] SX^RORSQRO]^\S]U]_LQ\Y_Z(O]^SWK^ONcOK\\S]U
YPQVK_MYWKKXNZ\ONSM^ON^ YLOK^cOK\]SX^ RK^]_LQ\Y_Z
35,58 In comparison, the lowest-risk subgroup (<6% esti-
WK^ONcOK\\S]UYPQVK_MYWKRKNKcOK\\S]UYPMYX`O\]SYXYPKXNKZ\ONSM^ON!\S]UK^cOK\]
35,58
Although knowledge of the factors that can predict the development of glaucoma is crucial, integrating this 
knowledge into the care of an individual OH patient is far from a simple, streamlined process. To help streamline 
this process and provide a consistent template with which to make evidence-based decisions, multiple predic-
tion models have been developed.94-960Y\^RO]OWYNOV]^YLOMYX	NOX^VcKMMOZ^ONLcZ\KM^S^SYXO\]^RO\OW_]^LO
some conclusive evidence to support their utility. Prediction models are developed from study populations and 
K]K\O]_V^MKXXY^KVaKc]LOQOXO\KVSdONLOcYXN^RK^]ZOMS	MZYZ_VK^SYX3^S]aSNOVcKMMOZ^ON^RK^KZ\ONSM^SYX
model should not be applied in clinical practice before it has been validated in at least one other population and 
preferably by different investigators.97 The most prominent validated risk prediction model available relies on 
pooled data from the observation group of the Ocular Hypertension Treatment Study and the placebo group of 
^RO/_\YZOKX1VK_MYWK:\O`OX^SYX=^_Nc/1:=
98
/1:=W_MRVSUO92>=]Y_QR^^YO`KV_K^O^ROOP	MKMcYP
reducing IOP to prevent or delay the development of POAG in patients affected by OH. EGPS was a multicenter 
randomized, double-blinded, placebo-controlled clinical trial involving 1,077 Caucasian subjects between 30 and 
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80 years of age with open angles, an IOP of at least 22 mmHg but not higher than 29 mmHg in one eye, and two 
XY\WKVKXN\OVSKLVO`S]_KV	OVN]
99
/1:=SNOX^S	ONW_V^SZVOZ\ONSM^S`OPKM^Y\]PY\^RONO`OVYZWOX^YPQVK_MYWK
that were highly consistent with OHTS, including older baseline age, larger vertical C/D ratio, higher PSD, and 
thinner CCT.100,K]ONYX^RO]OMYX]S]^OXMSO]K]aOVVK]Y^RO\UOc]SWSVK\S^SO]SX^ROS\\O]ZOM^S`ONO	XS^SYX]KXN
protocols, the OHTS and EGPS groups were able to collaboratively pool and analyze their data. This resulted in 
a more statistically sound risk-prediction model based on a larger number of participants and a larger number of 
POAG end points.97 From this prediction model the collaborating groups developed a risk calculator that could 
be useful in the clinic to assess an individual’s 5-year risk of conversion to POAG. There are two OHTS-EGPS 
based systems available for users of the calculator: one using a Cox proportional hazards model and one using a 
point system.97 These calculators may be accessed at http://ohts.wustl.edu/risk/calculator.html. Case examples 
are presented to demonstrate their appropriate use. The caveat is that these calculators will be most useful in 
patients with clinical characteristics similar to those of the patients enrolled in these studies.
Although the 5-year risk of converting to glaucoma from OH is a highly interesting piece of information, most op-
^YWO^\S]^]WKcXY^	XN^ RS]ZO\MOX^KQOZK\^SM_VK\VcWOKXSXQP_VSX^ ROS\^ \OK^WOX^NOMS]SYX]3X]^OKN^ ROKX]aO\]^ Y
more clinically relevant questions, such as; “Given what you see today, at what IOP would you have recommended 
IOP lowering?” and “If the patient were to come back in 6 or 12 months, all other things unchanged, how much 
higher would the IOP have to be for you to initiate treatment?” might be more meaningful for most practitioners. 
Jampel and Boland101 asked these exact questions and sought to provide evidence-based answers. Using data from 
the combined OHTS/EGPS analysis they developed a 5-year risk calculator, known as the “threshold to treat” cal-
culator, that produces an IOP, rather than percentage risk, at which treatment should be strongly considered.101 
This calculator may be accessed at http://oil.wilmer.jhu.edu/threshold. Since IOP is easily and often assessed, and 
^ROYXVcMVSXSMKVVcWYNS	KLVO\S]UPKM^Y\SXQVK_MYWKWKXKQOWOX^^RS]MKVM_VK^Y\\OZKMUKQO]^RONK^K^YZ\Y`SNO
information that is more commonly used and likely more relevant in practice. The threshold to treat calculator is 
clearly impactful, but has the same shortcomings as the OHTS/EGPS risk calculator: it captures only the static IOP 
acquired by tonometry at the time of recording, and fails to consider the dynamic nature of IOP, which is rarely 
completely assessed in the clinical setting. 101
CONFOUNDING FACTORS/CAPTURING IOP
Intraocular pressure is a dynamic process, the variation of which may confound risk assessment in patients with 
ocular hypertension. It is well known that IOP varies spontaneously over a 24hr period.102 Therefore, measure-
WOX^ SXKXYP	MO]O^^SXQ\O]_V^] SXKX SXMYWZVO^OZSM^_\O+V^RY_QR]O\SKV ^YXYWO^\cN_\SXQYP	MORY_\]WKc
LO^^O\MKZ^_\ONS_\XKV`K\SK^SYXZOKU39:RK]LOOX\OZY\^ON ^YYMM_\Y_^]SNOYPXY\WKVYP	MORY_\] SXWY]^
patients.103,104 In fact, Jonas et al.105 showed that any single IOP measurement acquired between 7:00 am and 9:00 
pm had a 75% probability of missing the peak of the 24hr IOP curve. Accordingly, IOP data gathered over a 24-hr 
period provides the most complete assessment of an individual’s risk characteristics. Grippo et al.106 compared 
the 24-hr IOP patterns of healthy patients to those of patients with untreated OH and early signs of POAG. After 
the investigators established baseline 24-hr IOP curves, patients were monitored over 4.3±3.8 years for glaucoma 
development. Diurnal and nocturnal curves were compared among the groups. Patients from the untreated OH 
group who converted to glaucoma manifested similar baseline 24-hr IOP curves as those in the initial glaucoma 
Q\Y_ZKXNaO\ONS]]SWSVK\^YLY^R^ROROKV^RcMYX^\YV]KXNXYXMYX`O\^O\]=ZOMS	MKVVcLY^R^ROMYX`O\^O\]KXN
initial glaucoma group exhibited higher diurnal mean IOPs as well as greater diurnal IOP variation compared to 
healthy controls. Although continuous IOP-measuring devices are on the horizon, they are not yet practically us-
able.107>RS]]^_Nc]RYa]^RK^KM[_S\SXQW_V^SZVO39:\OKNSXQ]K^NSPPO\OX^^SWO]YPNKcSXKXYP	MOWKcZ\Y`SNO
adequate risk assessment, without capturing the true variability in 24-hr IOP. 
Diurnal assessment does not, however, account for the long-term variability of IOP measured at multiple examina-
tions over time. Bhorade et al.108 analyzed IOP data from the OHTS with the goal of describing the variability of IOP 
measurements within the same eye and between the right and left eyes over a 60-month period.108 They found that 
YPOcO]RKNKNSPPO\OXMOSX39:YP(LO^aOOX^aYMYX]OM_^S`O`S]S^]>ROWOKXKL]YV_^ONSPPO\OXMOSX39:
measured within the same eye between all consecutive visits was within 3 mmHg in 66%, between 3 and 5 mmHg 
SXKXN(WW2QSX+V^RY_QR^ROK_^RY\]XY^ON^RK^^RO]^\SM^]^_NcZ\Y^YMYV]VSUOVcWSXSWSdON^RO`K\S-
KLSVS^c^cZSMKVVc]OOXSXMVSXSMKVZ\KM^SMO^RO	XNSXQ]KNNS^SYXKVVcRSQRVSQR^^ROMYWZVObS^cYPYL^KSXSXQMYX]S]^OX^
IOP data from which to adequately assess risk in ocular hypertensives. 
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Independent of the physiological properties of IOP, over-detection secondary to systematic errors in tonometry 
may lead to unnecessary treatment, resulting in an undue burden of treatment on the patient. Conversely, under-
detection and treatment may have dire consequences with respect to vision. In clinical practice, measurement of 
IOP is compulsory and used to screen for high-risk characteristics and monitor variations in the disease state, as 
aOVVK]^YO`KV_K^O^ROOP	MKMcKXNOPPOM^S`OXO]]YP^\OK^WOX^7Y]^Z\KM^SMO]_]O1YVNWKXXKZZVKXK^SYX^YXYWO^\c
to achieve these purposes. Both Goldmann applanation and non-contact tonometers are known to produce clini-
MKVVc]SQXS	MKX^]c]^OWK^SMO\\Y\]SPSXKNO[_K^OVcWKSX^KSXONKXNMKVSL\K^ON
109-113 An analysis of IOP data from 3,654 
participants in the Blue Mountains Eye Study revealed that a tonometer that consistently under- or over-reads by 1 
mmHg will miss 34% of individuals with OH or yield 58% more positive screening tests, respectively.114 This study 
underscored the need to maximize the repeatability of measurements through calibration.
In the actual management of glaucoma or ocular hypertension, the aforementioned historical assumption that day-to-day 
IOP variation is repeatable at any given time has led to the widespread practice of quarterly “pressure checks”, performed 
K^]SWSVK\^SWO]YPNKc^YROVZ^ROZ\KM^S^SYXO\QK_QO^ROOP	MKMcKXNOPPOM^S`OXO]]YP^ROS\Z\O]M\SLON^\OK^WOX^
115 Any 
difference in IOP from baseline is then attributed to the effect of medication or patient non-adherence. Multiple studies 
have shown that diurnal IOPs and the measurement of these IOPs are not repeatable in the short term in treated glau-
comatous individuals.116-120 Rotchford et al.115ObKWSXON^ROT_]^S	MK^SYXPY\NO^O\WSXSXQ^ROOPPOM^S`OXO]]YPWONSMK^SYX
using the traditional time-of-day standardized approach in treated patients with ocular hypertension. The variation of 
repeated IOP measurements in treated OH patients at the same time on different days lies within a range between ±21.2% 
and ±23.1% from baseline. The authors concluded that, even under ideal conditions, a day-to-day variability of ±20% sig-
XS	MKX^Vc_XNO\WSXO]LY^R^ ROZ\OMS]SYXYP39:WOK]_\OWOX^KXN^ ROO]^SWK^SYXYPWONSMK^SYXOPPOM^S`OXO]]O`OXaROX
the time of day is standardized.115 These studies suggest that optometrists should obtain multiple IOP readings prior to 
assessing the success or failure of therapy in OH patients they elect to treat. A clinical assumption that an ineffective 
treatment is effective and conversely that an effective treatment is ineffective carries multiple risks and only increases the 
potential burden on the patient, which can avoided by the careful practitioner. 
VALUE OF A RISK CALCUL ATOR IN PRACTICE
Although the OHTS-EGPS risk calculator has been shown to be accurate in multiple populations, the application 
KXN SX
_OXMOYP ^RS]MKVM_VK^Y\ SX \Y_^SXOZ\KM^SMOMKXLONOLK^ONKXNWKcO`OXWOO^aS^R \O]S]^KXMOLc ]YWO
ZRc]SMSKX]+]^_NcMYXN_M^ONLc7KX]LO\QO\KXN-SYP	
121 compared the ability of ophthalmologists to estimate 
an individual’s risk of converting to glaucoma to the results of a risk calculator. They showed that there was a high 
range of probability estimates among practitioners, which could potentially lead to under- and over-treatment and 
underscores the need for a tool that would give consistent results.
Boland et al.122 studied whether physician subspecialty training, access to a formal risk calculator or patient age 
SX
_OXMONZRc]SMSKX^\OK^WOX^\OMYWWOXNK^SYX]SXMK]O]YP92?]SXQ^RO\O]_V^]P\YW92>=^ROK_^RY\]QOX-
O\K^ON]SW_VK^ONMK]O]MOXK\SY]>RO]O]MOXK\SY]_]ON^RO\S]UPKM^Y\]SNOX^S	ONLc92>=PY_XNSX^RO\S]U
calculator, in addition to the patient’s diabetic status. One hundred eighteen members of the American Academy of 
Ophthalmology and 58 members of the American Glaucoma Society participated in this study by reviewing these 
cases with and without an estimated risk of conversion. The authors determined that inclusion of the risk calculator 
]SQXS	MKX^Vc SXM\OK]ONZRc]SMSKXMYX	NOXMOKXN\ON_MON SXMYX]S]^OXMc SX ^RONOMS]SYXWKUSXQZ\YMO]]=ZOMS	-
cally, addition of the risk calculator decreased the threshold to treat from a 22% risk of conversion over 5 years to 
17% in glaucoma subspecialists, and from 16% to 13% in a non-glaucoma-trained group.122 They concluded that, at 
least in simulated cases, the participating physicians underestimated the risk of developing glaucoma. This study 
]_ZZY\^] ^ROZY^OX^SKVYP ^RO\S]UMKVM_VK^Y\^YZ\Y`SNOWY\OMYX	NOX^KXNKMM_\K^OWKXKQOWOX^aRSMRaY_VN
hopefully reduce the functional consequences of under-treatment. 
:\KM^SMKVVcSP^RO\S]UMKVM_VK^Y\S]^YLOK^\_Vc_]OP_VNOMS]SYX]_ZZY\^^YYVS^aY_VNXOON^YRK`O]SQXS	MKX^SX^O\
visit repeatability, in a non-study, real-world clinical setting. Song et al.123 investigated the longitudinal variability of 
the risk calculator in a glaucoma referral practice. They reviewed the charts of 27 untreated OH patients for a mean 
of 98.3±18.5 months. Using the OHTS/EGPS risk calculator to calculate glaucoma risk for each patient at each fol-
low-up visit, they determined that the 5-year estimated risk of conversion to POAG among untreated patients varied 
]_L]^KX^SKVVc_Z^ YPYVNN_\SXQPYVVYa_Z=ZOMS	MKVVc^ ROLK]OVSXO\S]UYPMYX`O\]SYXaK]± 12.0% (range 2.9 
^Y#SX^ROXYX:9+1Q\Y_ZKXN±\KXQO^YSX^ROQ\Y_Z^RK^NO`OVYZON:9+1123 The re-
sults of this study highlight the danger in making decisions based on a single risk calculation. In daily practice, data 
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ZYSX^]MKXObRSLS^]_L]^KX^SKV
_M^_K^SYX]WY]^XY^KLVcPY\39:PY\aRSMRMYWZVO^ONS_\XKVKXNXYM^_\XKVM_\`O]
are not routinely obtained. The authors concluded that “ultimately, the availability of and access to a risk calcula-
tor does not guarantee widespread adoption by clinicians, nor does the data derived from that calculator, although 
compelling in spite of variability, mandate its use at this juncture”.123 
EFFECTIVENESS OF TREATMENT
When interpreting the results of any randomized clinical trial, it is important to determine whether a sta-
tistically significant result is also clinically significant. Clinical significance refers to the size of a treatment 
effect at which a clinician feels adoption of a treatment modality would be justified in clinical practice.124 The 
uX_WLO\XOONON^Y^\OK^v88>RK]LOOX_]ON^YKZZVc`KVSN]^K^S]^SMKVVc]SQXSPSMKX^\O]_V^] ^Y^ROMK\OYP
individual patients. Since we cannot precisely know which patients will benefit from treatment, the NNT gives 
an estimate of how many individuals will need treatment before any one patient will realize a benefit.125 NNT 
is derived by calculating the inverse of the absolute risk reduction.126 An ideal NNT is 1; treatment of 1 patient 
prevents 1 harmful outcome. Although NNT has been used to apply the results of RCTs to individuals, it is a 
statistical construct based on averages from these RCTs.57 The caveat is that these NNTs are not perfectly ap-
plicable to individuals who do not resemble patients from the RCTs. Nonetheless, NNT provides some under-
standing and general guidance that is not otherwise apparent in assessing the value of prophylactic treatment 
in patients with OH. In fact, when clinicians and policymakers have been presented with research results in 
different formats, they made more conservative decisions when they received treatment effects expressed as 
NNTs than when they received them as relative or absolute risk reductions.127
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+XObKWZVOYPK88>MYWO]P\YW^RO	OVNYPMK\NSYVYQc3XKWO^KKXKVc]S]YP<->]!""^Y^KV]_LTOM^]
^RK^ObZVY\ON^ROLOXO	^YP]^K^SX_]OSXZOYZVOaS^RY_^O]^KLVS]RONMK\NSY`K]M_VK\NS]OK]OL_^aS^RMK\NSY`K]M_-
lar risk factors, Brugts et al.128 assessed all-cause mortality and major coronary and cerebrovascular events, and 
found that the respective NNTs were 167, 77, and 250, respectively. In this example, 250 patients would require 
treatment to prevent one major cerebrovascular event. Further, if the treating doctor considers that this low po-
tential of success outweighs the burden of treatment, then they accept the fact that they will be unable to predict 
aRSMRYP^RY]OZK^SOX^]aSVVLOXO	^P\YWLORK\WONLcKXNLO_XKPPOM^ONLc^RO^\OK^WOX^3^S]SWZY\^KX^^Y
note that, although a NNT of 250 seems prohibitively high relative to an ideal of 1, it is inappropriate to compare 
NNTs across disease states of varying severities. NNT is a function of the severity of the disease, the intervention 
undertaken, and the likely outcome.127
This clinical conundrum of who to treat is no different in the case of ocular hypertension, although the NNTs 
may be more or less acceptable depending on how the clinician views the severity of the potential outcome. The 
10-year estimated incidence of POAG was reduced by approximately 50% in all three OHTS risk subgroups, con-
sistent with the relative risk reduction found at the 5-year point of the study.35 The absolute risk reduction in each 
subgroup may be a more useful statistic than measuring the relative risk reduction, which can be misleading in 
that individuals with substantially different absolute risks may have the same relative risk percentage. The abso-
lute risk reduction is the difference in the rate of an outcome, POAG in this case, in the control group minus that 
rate in the treatment group.124 In the lowest-risk subgroup 7% of the observation group and 4% of the treatment 
group developed POAG, an approximate 50% risk reduction, but a minimally convincing absolute risk reduction 
of just 3% over 10 years.35 /bZ\O]]ONSX88>NS`SNONLcZK^SOX^]aY_VNXOON^Y_]ONKSVcOcON\YZ]
PY\cOK\]^YZ\O`OX^YXOZK^SOX^P\YWNO`OVYZSXQ:9+1K]NO	XONLc^RO92>=M\S^O\SYX3X^RORSQRO]^\S]U
subgroup, at 10 years, 42% and 19% of the cases in the observation and treatment groups, respectively, developed 
:9+1PY\KX+<<YPKXNK88>YPKZZ\YbSWK^OVcNS`SNONLc3^MKXLOK]]O\^ON^RK^^\OK^SXQ
patients with daily medications over 10 years to prevent a case of glaucoma is more impactful than treating 33 to 
achieve the same result. The NNTs found in the 13-year review of the low-, moderate- and high-risk subgroups 
P\YWZRK]O33aO\O#" KXN!\O]ZOM^S`OVcaRSMRMYX]^S^_^O]KNNS^SYXKVO`SNOXMO^RK^^ROLOXO	^YP^\OK^WOX^
is most evident in the group with higher baseline risk.15 In summary, NNT can be a valuable part of decision-mak-
SXQ?XPY\^_XK^OVcS^PKSV]^YZ\ONSM^aRSMRYP^RO^\OK^ONZK^SOX^]aSVVLOXO	^P\YW^\OK^WOX^6SUOKVV\O]OK\MR
results, NNT should not be used in isolation, but rather should be integrated with patient preferences, caregiver 
experience and judgement, and local constraints and conditions.127
AROXMYX]SNO\SXQK^\OK^WOX^t]OP	MKMcS^S]KV]YM\S^SMKV^YK]]O]]^RO]SQXS	MKXMOYP^RO^\OK^WOX^t]KN`O\]OOP-
POM^]>RS]Z\Y`SNO]KMYWZ\OROX]S`OK]]O]]WOX^YP^RO\S]ULOXO	^\K^SYSX^\OK^WOX^>\OK^WOX^]KPO^caK]WYXS-
tored throughout OHTS, and there was no evidence of excess risk in the medication group for reported symptoms, 
overall number of new medical conditions, worsening of preexisting conditions, hospitalizations, or mortality.33 The 
K_^RY\]]_QQO]^ON^RK^^RO]O]KPO^c	XNSXQ]]_ZZY\^^ROXY^SYX^RK^^RO^\OK^WOX^Z\Y^YMYVSX^RK^]^_NcaK]]_M-
MO]]P_V>RS]PK`Y\KLVOLOXO	^Z\Y	VOKV^RY_QRXY^ZO\POM^VcKZZVSMKLVOY_^]SNOYP^RK^]^_Nc]RY_VNP_\^RO\KVVKc
concerns about treatment.
The use of healthcare resources is, by economic measures, not worthwhile unless there is a corresponding ben-
O	^/`KV_K^SXQ^ROOMYXYWSM`KV_OYPK^\OK^WOX^S]KXKNNS^SYXKVaKc^YK]]O]]K^\OK^WOX^t]OPPOM^S`OXO]]>RO
OHTS group analyzed the cost-utility of treatment on a hypothetical cohort of people with an IOP*24 mmHg. 
0Y_\^\OK^WOX^^R\O]RYVN]aO\OMYX]SNO\ON$^\OK^XYYXO%^\OK^^RY]OaS^RK*5% annual risk of developing 
QVK_MYWKKZZ\YbSWK^OVcYP^RO]_LTOM^]SX92>=%^\OK^ZOYZVOaS^RK*2% annual risk of developing 
:9+1KZZ\YbSWK^OVcYP^RO]_LTOM^]SX92>=KXN^\OK^O`O\cYXO>RO`KV_OYP^\OK^WOX^aK]LK]ON
YXRYa^RK^SX^O\`OX^SYXSWZKM^ON^ROZK^SOX^t][_KVS^cYPVSPOObZ\O]]ONSX[_KVS^cKNT_]^ONVSPOcOK\];+6C
14 
>\OK^WOX^ S]MYX]SNO\ON ^YLOMY]^OPPOM^S`O SP ^RO`KV_OZVKMONLc]YMSO^cYX ^RO;+6CObMOON] ^ROMY]^ ^RK^
]YMSO^caY_VNObZOXN^YKM[_S\O^RK^;+6C
129 The authors concluded that the treatment of patients with an IOP 
of *24 mmHg and a *2% annual risk of developing glaucoma is likely to be cost-effective.14 This is equivalent 
to a *\S]UYPNO`OVYZSXQQVK_MYWKSX^ROcOK\\S]UZO\SYN_]ONSX92>=>RS]]SQXS	O]^RK^ S^aY_VNLO
cost-effective to treat approximately 30% of patients resembling the study group from OHTS. For an additional 
perspective on this *2% annual risk threshold, Boland et al.130 assessed the threshold to treatment tolerance of 
glaucoma specialists, and found an average tolerance of a 4.6% annual risk of developing glaucoma without and 
a 3.4% annual risk with a risk calculator. This indicates that subspecialists are willing to treat approximately 10% 
of patients involved in OHTS. Therefore, a 2%/year threshold to treat could be considered fairly liberal, relative 
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to subspecialist clinicians, and still be cost-effective. Kymes et al.131KV]YVK^O\O`KV_K^ON^ROSX
_OXMOYPKZK^SOX^t]
life expectancy on the cost-effectiveness of preventative treatment. They concluded that, assuming a willingness 
to treat approximately 30% of OHTS participants, an OH patient would need to live at least an additional 18 years 
to make treatment cost-effective to society. In higher-risk categories, the required life expectancy would be re-
duced to 7 to 10 years.131 Although cost-effectiveness is, undoubtedly, a less personal model of the effectiveness of 
treatment, it still provides an additional perspective.
TREATMENT 
As previously mentioned, the treatment goal in OHTS, was to achieve a minimum 20% reduction from the aver-
age of the qualifying IOP and the IOP at the baseline randomization visit.28 The 20% target IOP was considered to 
\O
OM^M_\\OX^MVSXSMZ\KM^SMOK^^RO^SWOKXNS]]^SVVMYX]SNO\ONK\OK]YXKLVOSXS^SKV^K\QO^SXWKXKQSXQ92ZK^SOX^]
who are at a moderate risk of conversion.34,132-136 When OHTS was initiated, 94% of participants were prescribed 
topical -adrenergic antagonists ( LVYMUO\]SXKXK^^OWZ^^YWOO^^RK^^K\QO^137 Notably, none of the patients ini-
^SKVVc_]ONZ\Y]^KQVKXNSXKXKVYQ_O]:1+]N_O^Y^ROS\ VKMUYPK`KSVKLSVS^cK^ ^RO]^K\^YP ^RO]^_Nc2YaO`O\K^
the end of phase I, close to 50% of patients were prescribed PGAs34. Mono-therapy with any agent was not always 
]_P	MSOX^^YKMRSO`O^RO^K\QO^39:\ON_M^SYX3XZRK]O3Y\WY\O^YZSMKVWONSMK^SYX]aO\OZ\O]M\SLONPY\#!
of participants, and 3 or more medications were prescribed for 9.3% of participants.34 In an OHTS comparison of 
the IOP response to  blockers and PGAs, PGAs reduced IOP by an average of 2.1 mmHg and 1.3 mmHg more than 
 blockers in African-American and Caucasian patients, respectively.137 Medeiros et al.138 reported that each 1-mm 
Hg-higher average follow-up IOP increased the risk of conversion from OH to glaucoma by 20%. This emphasizes 
^ROXOON^Y_]O^ROWY]^OP	MKMSY_]WONSMK^SYXSX^RO]OMK]O]>RO\OPY\O:1+]K\O^ROSXS^SKVWONSMK^SYXYPMRYSMO
in the goal of at least a 20% or greater IOP reduction in treated OH patients. 
+V^RY_QR]OVOM^S`OVK]O\^\KLOM_VYZVK]^c=6>S]XY^aSNOVcOWZVYcONSXYZ^YWO^\SMMK\OS^S]KXKNNS^SYXKV	\]^
VSXO^RO\KZO_^SMYZ^SYX+WO^KKXKVc]S]YX^ROOP	MKMcYP=6>aS^RYZOXKXQVOQVK_MYWK]RYaON^RK^=6>S]XY^
inferior to medication for reducing IOP and achieving treatment success.139 In high-risk OH patients, Shazly et 
al.140NOWYX]^\K^ON^RK^=6>MKXLOZK\^SM_VK\VcLOXO	MSKVSX^RY]OaS^R-->YP&μm, with an effective dura-
tion of at least 30 months post-treatment. Several studies have also concluded that SLT may offer cost advantages 
over medical therapy. Lee and Hutnik141 compared the projected 6-year cost of SLT to topical medications in 
^RO9X^K\SY2OKV^R3X]_\KXMO:VKX923:PY\ZK^SOX^]aS^RYZOXKXQVOQVK_MYWKKQON KXNYVNO\,K]ONYX
the assumption that bilateral 180-degree SLT was repeated 3 years from the initial treatment, SLT resulted in a 
savings of $580.53, $2,042.82 and $3,366.65 per patient over mono-, bi- and tri-drug therapy, respectively, over 
that same 6 years.141 Seider et al.142]RYaON]SWSVK\	XNSXQ]SX^RK^=6>aK]VO]]ObZOX]S`O^RKXWY]^L\KXNXKWO
medications within 1 year and less expensive than generic latanoprost and generic timolol after 13 and 40 months, 
respectively. Stein et al.143 determined that both PGAs and laser trabeculoplasty are cost-effective options for the 
management of newly diagnosed mild open angle glaucoma compared to observation. Based on the assumption 
that patient adherence to topical medication is not 100%, they estimated that, at current PGA prices, laser tra-
LOM_VYZVK]^cWKcLOKWY\OMY]^OPPOM^S`OKV^O\XK^S`O^RKX:1+]?V^SWK^OVc^RO]OVOM^SYXYPK]ZOMS	M^YZSMKV
hypotensive medication or use of SLT will be determined by the individual patient’s systemic and ocular health 
status, risk tolerance and insurance factors.
CONCLUSIONS
The management of Ocular Hypertension is an ongoing challenge for the primary eye-care practitioner, and is compli-
cated by an uncertain disease course and evidence-based research showing that the vast majority of patients will not 
develop POAG. The evidence clearly supports the treatment of patients with high-risk characteristics and treatment 
YPKZZ\YbSWK^OVcYPZK^SOX^]MKXLOOMYXYWSMKVVcT_]^S	KLVO+QOROKV^R]^K^_]VSPOObZOM^KXMcL_\NOXYP^\OK^-
ment, quality of life, patient and practitioner risk tolerance and attitudes toward disease and treatment all add to the 
complexity of the decision-making process. The decision to treat is serious, since it potentially sentences the patient 
^YVSPOVYXQ^\OK^WOX^aS^RY_^KQ_K\KX^OOYPLOXO	^P\YW^RK^^\OK^WOX^.OMS]SYX]_ZZY\^^YYV]]_MRK]^RO92>=
EGPS risk calculator and “threshold to treat” calculator reduce uncertainty and provide direction that was previously 
unavailable. However, they are limited by variations in IOP and the ability to observe those variations. A patient-cen-
tered approach is necessary in cases where the absolute need to treat can be disputed. In concert with evidence-based 
risk assessment, this approach can effectively guide the optometrist and informed patient in enacting customized 
management that is appropriate for the individual.
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“Clinicians should make certain that their patients have a clear understanding regarding the risk of disease progres-
sion and its potential impact on their quality of life in advising them concerning treatment options. Those patients 
aRYK\OWY\O\S]UK`O\]OK\OWY\OVSUOVc^Y`SOa^\OK^WOX^K]LOXO	MSKVKV^RY_QR^RY]OZK^SOX^]aS^RQ\OK^O\^YVO\-
KXMOPY\\S]UYPZ\YQ\O]]SYXKXNKXK`O\]SYX^YWONSMK^SYXWKcZO\MOS`OVO]]LOXO	^vx>RO9M_VK\2cZO\^OX]SYX
Treatment Study Group
Illustrative Case
>RS]MK]OS]K^cZSMKVObKWZVOYP92OXMY_X^O\ONSXY_\Z\KM^SMOKXN\O
OM^]^ROMYWZVObS^cYPWKXKQOWOX^NO-
cisions in these patients. Our patient was a 70-year-old Caucasian male with a stable history of prostate cancer 
post-radiation and hormone therapy x 5 years, post-amputation secondary to peripheral vascular disease (currently 
YXaK\PK\SXKXNaOVVMYX^\YVVONRcZO\^OX]SYXKXNRcZO\VSZSNOWSK2S]SX^\KYM_VK\Z\O]]_\O]\KXQONP\YW
mmHg OD, OS, and the average of 8 IOP readings over the last 3 years was 28 mmHg. CCTs were 599 and 597 μm, 
respectively. Corneal hysteresis values were 10.5 mmHg and 10.7 mmHg, which are average for a Caucasian and 
MYXPO\XYKNNS^SYXKV\S]U9Z^SMXO\`O]0SQaO\OT_NQONLcW_V^SZVOObKWSXO\]^YLO9.9=KXNMZ<806
WOK]_\OWOX^]aO\O_X\OWK\UKLVO0SQ@S]_KV	OVN]0SQ]RYaONWSVNu\O`O\]OMK^K\KM^vZK^^O\X]SXOKMR
OcON_O^YZK^SOX^Y`O\ZO\PY\WKXMOYX^RS]SXS^SKV	OVN7.]aO\OLY^RZY]S^S`OKXN^RO\OaO\OXYQVK_MYWK^Y_]
defects. With the OHTS/EGPS risk calculators found at http://ohts.wustl.edu/risk/calculator.html, the point sys-
tem generates a 5-year estimated risk of POAG of 10% and 3.5% with the continuous method, using an average of 
28 mmHG. These percentages would fall in the moderate- and low-risk subcategories of OHTS, respectively. With 
the “Threshold to Treat” calculator at http://oil.wilmer.jhu.edu/threshold/, and with an estimated threshold for 
KcOK\\S]UYPZ\YQ\O]]SYXYP LK]ONK\LS^\K\SVcYX ^RO VYaO]^ZO\MOX^KQO SX ^RORSQRO]^\S]U]_LMK^OQY\c
the IOP threshold to initiate treatment exceeds 32 mmHg. After we educated the patient on his risk of developing 
glaucoma, the risk of functional loss from glaucoma, and what treatment would entail, we and the patient mutually 
decided to continue monitoring. This case perfectly illustrates the need to comprehensively assess the risk in OH 
beyond IOP, the critical role of CCT in increasing or decreasing that risk, and the burden of treatment relative to 
^ROVSUOVcLOXO	^YP^\OK^WOX^3X^RS]MK]O^ROW_^_KVNOMS]SYX^YNOVKc^\OK^WOX^aK]W_V^SPKM^Y\SKVKXNSXMV_NON
the patient’s poor health status, current burden of systemic medical therapy, age and limited life expectancy, risk 
assessment and the risk tolerance of both parties. A different patient with the same risk factors and different atti-
^_NO]^YaK\N\S]UKXN^\OK^WOX^WKcNO]S\O^\OK^WOX^aRSMR\OSXPY\MO]^ROXY^SYX^RK^^RO\OS]XYYXO]SdO	^]KVV
approach to these patients. 
Figure 1: ONH Photos
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Figure 2: -Zx<806
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Figure 3: Visual Fields
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